[144] Apellis Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Form 4 filing for Antero Midstream Corp. (AM) discloses that director Brooks J. Klimley acquired 2,042 shares of AM common stock on 07 July 2025. The shares were received at a stated price of $0.00, implying a grant rather than an open-market purchase. Following the transaction, Klimley’s direct beneficial ownership increased to 75,687 shares. No derivative securities were reported.

The filing is routine in nature, reflecting a modest change in insider ownership and does not provide additional financial or strategic information about Antero Midstream.

Insights

Financial Analyst

TL;DR: Small, routine insider share grant—neutral overall impact.

This Form 4 records a director’s receipt of 2,042 AM shares, raising total direct holdings to 75,687. At roughly sub-0.01 % of AM’s 478 million-share float, the transaction is immaterial to valuation or liquidity. Because the shares were granted at no cost, it neither signals market-price conviction nor alters cash flows. Insider alignment marginally improves, but the size is too small for trading significance. I assess the disclosure as neutral for investors.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	137465	2774922.05	125682260	07/14/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/12/2024	Restricted Stock Vesting	Issuer			13010	01/12/2024	Compensation
Common	02/10/2024	Restricted Stock Vesting	Issuer			4632	02/10/2024	Compensation
Common	01/21/2024	Restricted Stock Vesting	Issuer			16607	01/21/2024	Compensation
Common	01/28/2024	Restricted Stock Vesting	Issuer			3407	01/28/2024	Compensation
Common	01/21/2025	Restricted Stock Vesting	Issuer			16487	01/21/2025	Compensation
Common	01/16/2025	Restricted Stock Vesting	Issuer			12016	01/16/2025	Compensation
Common	01/28/2025	Restricted Stock Vesting	Issuer			3426	01/28/2025	Compensation
Common	01/12/2025	Restricted Stock Vesting	Issuer			2677	01/12/2025	Compensation
Common	07/14/2025	Options Granted - 08/21/2017	Issuer			65203	07/14/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many AM shares did director Brooks J. Klimley acquire on 07/10/2025?

2,042 shares were acquired, according to the Form 4 filing.

What is Brooks J. Klimley’s total direct ownership in Antero Midstream after the transaction?

The director now directly owns 75,687 AM shares.

Was the acquisition an open-market purchase or a grant?

The filing lists a $0.00 price, indicating the shares were granted, not bought on the market.

Does the Form 4 report any derivative securities for AM?

No—Table II is empty; no derivatives were reported.

Is this insider transaction considered material to Antero Midstream investors?

Given the small size relative to AM’s total shares outstanding, it is not deemed materially impactful.